CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for $299 in July, a $200 Savings Offer to Improve Access as WeightWatchers’ Trusted, Science-Backed Approach Continues to Lead the ...

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...

Retail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...

HC Wainwright initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:AARD) on Monday with a Buy rating and a price ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.